Ergotamine
| Ergotamine | |
|---|---|
| Salts [] | |
|---|---|
| Ergotamine hemitartrate | |
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 581.70 g/mol [1] |
| Appearance | Needles from alcohol; prisms from benzene; plates from acetone [1] |
| Melting point | 213.5 dec °C [1] |
| Decomposition | Decomposition at 212-214 °C. [1] |
| Solubility | Slight [1] |
| Predicted LogP | 2 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C33H35N5O5 |
| IUPAC name | (6aR,9R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide |
| SMILES | C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C |
| InChI | InChI=1S/C33H35N5O5/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32/h3-6,8-11,15,17,21,25-27,34,42H,7,12-14,16,18H2,1-2H3,(H,35,39)/t21-,25-,26+,27+,32-,33+/m1/s1 |
| InChIKey | XCGSFFUVFURLIX-VFGNJEKYSA-N |
| CAS number | 113-15-5 |
| UNII | PR834Q503T |
| PubChem CID | 8223 |
| Pharmacokinetics[] | |
|---|---|
| Elimination half-life | 2 hours |
| Metabolism | Liver |
| Excretion | 90% Bile duct |
| Routes of administration | Oral |
| Toxicity [] | |
|---|---|
| LD50 | Cat: - sc: 11 mg/kg Mouse: - iv: 62 mg/kg Rabbit: - iv: 100 mg/kg - iv: 3 mg/kg Rat: - iv: 80 mg/kg - Intravenous: 62 mg/kg [1] |
Ergotamine (also known as Ergotamin, Ergonsvine, Ergotamina, ergotaminum, 12'-Hydroxy-2'-methyl-5'α-(phenylmethyl)ergotaman-3',6',18-trione, (5'α)-12'-Hydroxy-2'-methyl-5'-(phenylmethyl)ergotoman-3',6',18-trione, Ergotaman-3',6',18-trione, 12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'-α)-, Ergo Kranit, Mono, Ergodryl or N02ca02) is a substance of the lysergamide class.
Chemistry
Salts []
Stereochemistry []
Ergotamine is a single defined stereoisomer.
Druglikeness
Lipinski's rule of five
Ergotamine matches Lipinski's rule of five (violations: 1).Pharmacology
ATC Classification
- nervous system (N)
- analgesics (N02)
- antimigraine preparations (N02C)
- ergot alkaloids (N02CA)
- ergotamine (N02CA02)
MeSH Classification
- oxytocics (M0015702)
- vasoconstrictor agents (M0022551)
- serotonin receptor agonists (M0026371)
- analgesics, non-narcotic (M0028038)
- adrenergic alpha-1 receptor agonists (M0543920)
Mechanism of action []
Ergotamine acts on migraine by one of two proposed mechanisms: 1) activation of 5-HT<sub>1D</sub> receptors located on intracranial blood vessels, including those on arterio-venous anastomoses, leads to vasoconstriction, which correlates with the relief of migraine headache, and 2) activation of 5-HT<sub>1D</sub> receptors on sensory nerve endings of the trigeminal system results in the inhibition of pro-inflammatory neuropeptide release. [1]
Interactions []
Interaction mechanisms documented in KEGG DRUG (number of interacting drugs):
| CYP3A4 | metabolism / induction / inhibition | 147 (7 contraindicated) |
|---|---|---|
| ADRA1A | shared target | 18 (2 contraindicated) |
| ADRA1B | shared target | 18 (2 contraindicated) |
| ADRA1D | shared target | 18 (2 contraindicated) |
| HTR1B | shared target | 14 (12 contraindicated) |
| HTR1D | shared target | 14 (12 contraindicated) |
| HTR1A | shared target | 10 |
Medical side effects []
22 side effects listed on drug labels in SIDER 4.1 (ergotamine).
- Asthenia
- Cyanosis
- Localised oedema
- Gangrene
- Hypertension
- Ischaemia
- Nausea
- Hypoaesthesia
- Sensory loss
- Pain
- Paraesthesia
- Paresthesia of limbs
- Pruritus
- Tachycardia
- Vertigo
- Vomiting
- Emotional distress
- Myalgia
- Musculoskeletal discomfort
- Pulse absent
- Peripheral coldness
- Bradycardia
Indications
- Headache
- Migraine
- Variants of migraine
- Vascular headache
Legal status []
See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 8223, Ergotamine. Accessed November 20, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/8223
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Ergotamine. UNII: PR834Q503T. Global Substance Registration System. Accessed November 20, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/PR834Q503T
RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. 31 March 2023. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992
Ergomar- ergotamine tartrate tablet, orally disintegrating. DailyMed. 8 September 2012. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1bfd4827-5123-4dbb-8f94-7b097f5bfd5c
Ergomar sublingual- ergotamine tartrate tablet. DailyMed. 25 October 2022. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dac9637f-3326-4f25-b7b9-f9f54b738232
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 03:05:31 |
| drugspro | missing (no DrugsPRO reagent data) | 2026-11-20 03:05:27 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 03:05:27 |
| gsrs | ok | 2026-11-20 03:05:28 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0014834) | 2026-11-20 03:05:27 |
| kegg | ok | 2026-11-20 03:05:29 |
| pubchem | ok | 2026-11-20 03:05:26 |
| missing (no r/tripreports posts mention it) | 2026-11-20 03:05:27 | |
| sider | ok | 2026-11-20 03:05:27 |
| structure | ok | 2026-11-20 03:05:27 |
| wikipedia | ok | 2026-11-20 03:05:27 |